CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
用于肿瘤免疫治疗的 CAR 工程化先天免疫细胞全景
英文原题：The landscape of CAR-engineered innate immune cells for cancer immunotherapy.
查看英文原题
The landscape of CAR-engineered innate immune cells for cancer immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞提高了淋巴系统恶性肿瘤患者的治愈率和生活质量，但尚未在实体瘤中显示出临床获益。因此，目前正在探索多种CAR工程改造策略，以克服CAR-T 细胞的功能局限性和高成本。其中的关键方向是CAR工程改造的固有免疫细胞，如自然杀伤（NK）细胞、NK T（NKT）细胞、T细胞和巨噬细胞。在本综述中，我们讨论了开发和使用固有免疫CAR工程改造细胞用于肿瘤免疫治疗的潜力和局限性。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cells have improved the cure rate and quality of life of patients with lymphoid malignancies but have yet to demonstrate clinical benefits in solid tumors.
Thus, several CAR-engineering strategies are currently being explored to overcome the functional limitations and the high cost of CAR T cells. Key among these are CAR-engineered innate immune cells, such as natural killer (NK) cells, NK T (NKT) cells, T cells and macrophages. In this Review, we discuss the potential and limitations of efforts to develop and use innate immune CAR-engineered cells for cancer immunotherapy.
论文信息
- 作者
- Tsahouridis O、Xu M、Song F、Savoldo B、Dotti G
- 第一作者单位
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.United States
- 通讯作者单位
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. gdotti@med.unc.edu.United States
- 文献类型
- 综述
- 期刊
- Nature cancer2025 Jul
- 原文标识
- PubMed 40681797 · DOI 10.1038/s43018-025-01015-z